Advancing HCC Trial Design with Targeted PET Tracers and LI-RADS, RECIST/mRECIST
Hepatocellular carcinoma (HCC) is not just a leading cause of cancer deaths but also has rising mortality and frequent resistance to therapy. Accurate staging and early detection directly influence eligibility for curative options and downstream outcomes. In clinical trials, integrating advanced molecular imaging with conventional CT/MRI can improve baseline staging, guide treatment allocation, and enable earlier assessment of response and recurrence — ultimately improving patient selection, endpoints, and decision-making.
Conventional imaging (i.e. ultrasound for surveillance and contrast-enhanced multiphasic CT/MRI for diagnosis) remains the gold standard for intrahepatic staging by using arterial phase hyperenhancement and washout to diagnose HCC without biopsy in at-risk patients. Yet sensitivity drops for small or atypical lesions and for early extrahepatic spread. PET can complement CT/MRI by characterizing tumor biology, and while 18F-FDG has limited sensitivity in well-differentiated HCC, alternative PET tracers such as 68Ga-PSMA, 18F/11C-choline, 11C-acetate, and newer FAPI agents have improved detection, staging accuracy, and management impact in emerging studies.
Imaging Endpoints (IE) leads the industry in the integration of advanced imaging in HCC trials through protocol design, standardization, and centralized reads spanning CT/MRI and PET. LI-RADS-consistent multiphasic liver imaging with RECIST 1.1, mRECIST lesion characterization, and deploying hybrid PET/CT or PET/MRI can be critical for staging or treatment. IE has extensive experience coordinating multi-modality packages that combine pharmacodynamic biodistribution assessment with high-quality anatomic and functional imaging.
Recent developments show 68Ga-PSMA improves whole-liver evaluation and detects more distant metastases than CT. Choline and acetate tracers complement FDG by capturing well-differentiated tumors and sub-centimeter lesions; dual-tracer strategies increase sensitivity and improve transplant selection and TACE/SIRT response assessment. FAPI imaging has demonstrated higher sensitivity than FDG for intrahepatic lesions, better small-lesion detection, and frequent upstaging with management changes. Carefully curated multimodal workflows that combine standardized RECIST/mRECIST reads with targeted PET biodistribution, and skeletal assessments can prospectively enrich cohorts and enable adaptive strategies (including PET-guided re-treatment after SIRT), improving endpoint power without compromising patient safety or blinding.
Advanced imaging is redefining HCC trials integrating rigorous CT/MRI standards with novel PET tracers and high-level biodistribution workflows to enhance staging, treatment allocation, and response assessment. IE is at the forefront with a flawless inspection record and a 95% marketing authorization success rate – reflecting disciplined quality and strategic imaging science.
Reach out to us to connect with our experienced medical and scientific experts and explore how our tailored imaging solutions can support your HCC clinical trials. For more information,
